Don’t know how many of you got signed up for ark’s emails about big gainers and losers. I didn’t jump into any of these directly, pacb being the big miss. I got arkg though.
CM Life Sciences (CMLF), a special purpose acquisition company (SPAC), surged
15% on Friday after
announcing its plan to combine with Sema4, a population-scale health intelligence company. Unlike many legacy molecular diagnostics companies, Sema4 has focused on developing a platform instead of a diagnostic product. In our view, Sema4's genomics acumen, epidemiological expertise, and emphasis on longitudinal patient care should yield a more engaging and effective experience for large health systems. Studying patient transitions from health to illness across large and diverse groups, Sema4 should be able to help physicians intervene before diseases become intractable.
Pacific Biosciences (PACB), a leader in highly accurate and comprehensive DNA, RNA, and epigenetic sequencing, traded up
16% on Wednesday after disclosing that Softbank had invested
$900 million via convertible debt. In our view, Softbank’s investment will allow PacBio to accelerate the cost- and price-decline of its highly accurate long-read technology (HiFi), pursue a more aggressive R&D schedule, and drive commercialization efforts faster than otherwise would be the case. HiFi sequencing should become the standard for whole genome sequencing across clinical, research, and population efforts, thanks to its
accuracy, ability to phase mutations to maternal or paternal haplotypes, comprehensive variant detection, and native epigenetic detection. Though more expensive than short-read sequencing, the value of HiFi-sequenced genomes seems to be higher. As PacBio drives down prices and increases system throughput, many applications are likely to migrate to HiFi technology.
Longview Acquisition Corporation (LGVW), a special purpose acquisition company (SPAC) that is acquiring Butterfly Network, closed up
18% on Monday. In our view, investors and speculators are building positions prior to the
consummation of the merger on or around February 16th. Butterfly is a medical technology company focused on democratizing access to point-of-care ultrasound (POCUS) devices. Unlike other centralized and handheld POCUS instruments, Butterfly's technology uses a proprietary semiconductor-based, AI-assisted ultrasound system instead of a system based on piezoelectric crystals. Butterfly's technology seems to be a more cost-effective, robust, and differentiated tool for medical imaging.
, i dont even sell them for a gain since i reinvest back into the company. IRS can kiss my azz
”
